Related Experiment Video
Updated: Sep 2, 2026

Intra-Omental Islet Transplantation Using h-Omental Matrix Islet filliNG (hOMING)
Published on: March 14, 2019
Generic Long-Acting Injectable Product Availability and Approval Standards
Krista Anim Anno1,2, Doortje Esther Lubberts3,4, Lei Zhang1
1Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, 20993, USA.
Purpose:
Long-acting injectables (LAIs) offer substantial clinical and economic advantages, including improved patient adherence, enhanced safety and efficacy, and reduced overall healthcare costs. Despite these benefits, the availability of generic LAIs remains limited, largely due to the complexity of formulation development and regulatory assessment. This study aimed to characterize the landscape of LAI product availability, regulatory frameworks, and approval standards in the United States and Europe, and to identify opportunities to support generic LAI development.
Methods:
A comparative analysis was conducted of LAI product approvals through December 2025, along with regulatory guidance documents issued by the U.S. Food and Drug Administration (FDA) through February 2026, the European Medicines Agency (EMA) through December 2025, and European national agencies through July 2023.
Results:
The FDA approved 64 distinct new LAIs via the 505(b)(1) and 505(b)(2) pathways and 13 generic LAIs via the 505(j) pathway. In contrast, new and generic LAIs covering 26 and 15 active pharmaceutical ingredients (API), respectively, were approved by the EMA and European national agencies. The FDA issued 48 product-specific guidances (PSGs) for LAIs, whereas the EMA published five PSGs in addition to general modified-release guidance documents. Both agencies issued PSGs for five shared LAI products: exenatide, lanreotide, octreotide, and paliperidone palmitate (1-month and 3-month formulations). Comparative review of these PSGs revealed both alignment and differences in bioequivalence recommendations. Global collaborative efforts to promote generic LAI development were highlighted.
Conclusions:
These findings provide a foundation for harmonizing generic LAI approval standards, which may improve resource allocation, promote generic competition, and enhance patient access to LAI therapies.
Related Concept Videos
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into rapid-acting...
Drug Products: Biologics, Biosimilars and Interchangeables
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
FDA Approved Drugs: Changes to Approved Drugs
Pharmaceutical Equivalents
Clinically Relevant Drug Product Specifications: Methods of Establishment
